Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06807918 · ClinicalTrials.gov registry record · Phase 2

Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder

A Phase 2 study, sponsored by University of Pennsylvania.

Not yet
Registry status
Phase 2
Development phase
60
Enrollment target

NCT06807918: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.

NCT06807918 is a Phase 2 study that has not yet begun recruiting, run by University of Pennsylvania. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06807918, a Phase 2 study, has not yet begun recruiting, sponsored by University of Pennsylvania.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

This is a randomized, double-blind, crossover trial to evaluate the immediate effects of a nutritional ketone supplement, Kenotic compared to placebo on brain function and alcohol consumption in individuals with alcohol use disorder. Participants will complete 2 MRI scans, 2 FDG PET/CT scans, and 2 alcohol bar labs and will randomly receive Kenetik at one lab and the placebo at the next lab. During the bar labs participants will consume a dose of alcohol (based on weight), to bring their breath alcohol concentration to about 0.050%.

Primary Outcome

The primary outcome measure to be analyzed is a comparison of a single dose of KS versus placebo in AUD subjects in the amount of FDG uptake (CMRg metabolic rate of glucose) (mmol/L) levels in the brain.

Interventions

  • DIETARY_SUPPLEMENT Kenetik
  • OTHER Placebo beverage
  • OTHER magnetic resonance imaging scan
  • OTHER fludeoxyglucose-18 positron emission tomography scan
  • OTHER Alcohol bar lab

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-08-01
Est. Completion 2030-01-01
Phase Phase 2
University of Pennsylvania

1,423 total trials

What is known before NCT06807918 opens enrollment

NCT06807918 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 5 interventions - of which Kenetik is the first listed.

NCT06807918 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06807918 about?

NCT06807918 is a clinical study titled "Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder". This is a randomized, double-blind, crossover trial to evaluate the immediate effects of a nutritional ketone supplement, Kenotic compared to placebo on brain function and alcohol consumption in individuals with alcohol use disorder. Participants will complete 2 MRI scans, 2 FDG PET/CT scans, and 2 ...

What is the current status of trial NCT06807918?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-08-01. Estimated completion is 2030-01-01.

What interventions are being tested in trial NCT06807918?

The interventions under investigation include: Kenetik (DIETARY_SUPPLEMENT), Placebo beverage (OTHER), magnetic resonance imaging scan (OTHER), fludeoxyglucose-18 positron emission tomography scan (OTHER), Alcohol bar lab (OTHER).

Who is sponsoring clinical trial NCT06807918?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06807918's enrollment target sits among peer trials

60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06807918, the US trial registry maintained by the National Library of Medicine. NCT06807918 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.